Javier García has spent almost 30 years working in healthcare and the biopharmaceutical industry and has focused on life science venture capital investing since 2009, where he focuses on private company investments in the biopharmaceutical, life science and medical technology sectors.
Javier García spent 25 years at Eli Lilly and Company. He had senior management roles in Information Technology and Business Development. He got in charge of Business Development activities for the BioMedicines business unit in USA, Europe and Japan (that included all the Therapeutic Areas except for Oncology and Diabetes). During his time in Business Development (2009 to 2012) 5 deals were accomplished (license agreement of Incyte Autoimmune portfolio, Axiron estosterone license, Alnara acquisition, Cymbalta buy back from Boeringher Ingleheim, and Amyvid acquisition). Led the Lilly team to the first closing of the 140 million fund with TVM where Lilly was a strategic limited partner. Mr. García serves on the Board of several Biotech companies: Artax Biopharma (based in Boston,MA), Bioncotech (based in Valencia, Spain) and Inveready Biotech II (a Spanish Venture Fund based in based in Barcelona. Spain). He is a founder investor and board member of Aura Biosciences (Boston, MA) . He also serves on the board of the National Alliance for Hispanic Health and the Healthy Americas Foundation.
Mr. García received a Bachelor in Mathematics (Statistics and Operations Research) from Universidad Complutense of Madrid and a MBA from ICADE (Spain). He is fluent in English and Spanish.